Categories Side Effects



Relevance: High


Strength of Science: High


Research Timeline: Post Approval
30 April 2025
Study : Two immunotherapy drugs are better than one for some metastatic colorectal cancers
Most relevant for: People with unresectable or metastatic colorectal cancer that is MSI-High or dMMR
Combining two immunotherapy drugs is a more effective treatment for certain metastatic colorectal cancers than using either treatment drug alone. Used together, Opdivo (nivolumab) plus Yervoy (ipilimumab) slowed cancer growth in MSI-High metastatic colorectal cancers, a type of colorectal cancer often found in Lynch syndrome. The FDA approved this combined treatment for MSI-High metastatic colorectal cancer after progression with chemotherapy. (Posted 4/30/25)
READ MORE ›


Relevance: Medium-High


Research Timeline: Post Approval
28 February 2025
Topic : Addressing the needs of young adults with breast cancer
Most relevant for: Young women with breast cancer concerned about survivorship issues
This update addresses common concerns faced by young adults with breast cancer, particularly fertility and childbearing, psychosocial health and treatment-related side effects. (Posted 2/28/25)
Este artículo está disponible en español.
READ MORE ›


Relevance: Medium-High


Strength of Science: Medium-High
27 September 2024
Study : Use of cannabis for cancer symptom management
Most relevant for: People with cancer interested in using cannabis to help manage symptoms.
Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)
Este artículo está disponible en español.
READ MORE ›


Relevance: Medium-High


Strength of Science: Medium-High


Research Timeline: Post Approval
25 September 2024
Study : Managing the side effects of advanced endometrial cancer treatment
Most relevant for: People with advanced endometrial cancer
Immunotherapy plus targeted therapy is a treatment option for advanced endometrial cancer that has progressed after prior treatment. People who start the two-drug combination are more likely to have a positive experience if they learn about the possible side effects and when they might occur. The most common side effects and how to manage them are discussed in this review. (Posted 9/25/24)
Este artículo está disponible en español.
READ MORE ›


Relevance: Medium


Research Timeline: Post Approval
10 September 2024
Update : News from the FDA: First-line treatment and biosimilars for prostate cancer
Most relevant for: People with prostate cancer
The FDA recently approved a first-line treatment for non-metastatic, castration-sensitive prostate cancer. Approval was also given to two new drugs known as biosimilars that can be used in place of two already approved biologics to prevent bone weakening, pain or fractures that may occur from certain hormone therapies or from cancer that has spread to the bone. (Posted 9/10/24)
Este artículo está disponible en español.
READ MORE ›


Relevance: High


Research Timeline: Post Approval
7 August 2024
Topic : Acupressure for cancer symptom relief
Most relevant for: People diagnosed with cancer
Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)
Este artículo está disponible en español.
READ MORE ›


Relevance: Medium-High
17 July 2024
Topic : Experts call for early palliative care for cancer patients
Most relevant for: Cancer patients
People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)
Este artículo está disponible en español.
READ MORE ›


Relevance: Medium-High


Quality of Writing: High
21 September 2023
Topic : Sexual health concerns of gay and bisexual men with prostate cancer
Most relevant for: Gay and bisexual men diagnosed with prostate cancer
Prostate cancer therapy can affect gay and bisexual men differently than heterosexual men. Many urologists do not routinely address these unique concerns. Selecting providers who understand the concerns that are unique to gay and bisexual patients and asking questions about sexual health concerns may improve these patients' healthcare experiences. (Posted 9/21/23)
Este artículo está disponible en español.
READ MORE ›


Relevance: Medium-High
8 August 2023
Topic : Sex and intimacy after breast cancer
Most relevant for: People with breast cancer or metastatic breast cancer in sexual or intimate relationships and their partners
A breast cancer diagnosis and treatment can affect relationships with romantic partners. This review highlights two studies that looked at how people with breast cancer and their partners are affected, how they cope, how best to communicate with each other and how to talk with healthcare providers about concerns related to cancer and sexuality. (Posted 8/8/23)
Este artículo está disponible en español.
READ MORE ›


Relevance: High


Strength of Science: High
27 February 2023
Study : Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people
Most relevant for: People with early-stage breast cancer who are post-menopausal
A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)
Este artículo está disponible en español.
READ MORE ›